Managing anaemia in renal failure

Pharmaceutical Journal

Volumn 273, Issue 7322, 2004, Pages 603-605

  Sexton, John ^a,b   Vincent, Marc ^a  

^a ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; FERRIC HYDROXIDE SUCROSE; HEMOGLOBIN; IMMUNOSUPPRESSIVE AGENT; IRON; IRON DERIVATIVE; IRON DEXTRAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ABDOMINAL PAIN; ANAPHYLAXIS; ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CONSTIPATION; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL DISEASE; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; IRON DEFICIENCY ANEMIA; IRON THERAPY; KIDNEY FAILURE; NAUSEA; NOTE; PATHOGENESIS; PRACTICE GUIDELINE; PURE RED CELL ANEMIA; THROMBOSIS; VOMITING;

EID: 8344228470     PISSN: 00316873     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (3)

1. Locatelli F, Alijama P, Barany P, Canaud B, Carrera F, Eckkardt KU et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrology Dialysis Transplantation 2004;19 (Suppl 2): ii1-47.
2. Renal Association. Adult Seciton 7: Anaemia in patients with chronic renal failure. Treatment of adults and children with renal failure: Standards and audit measures. 3rd Edition. London: Royal College of Physicians: 2002. Available at www.renal.org/Standards/RenalStandards_2002b.pdf (accessed 28 September 2004).
3. Dreicher R, Horl WH. differentiating factors between erythropoiesis-stimulating agents. Drug 2004;64: 499-509.